Recent news on Trisenox

CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ...  -  May 1, 2007
MedIndia,The alleged "off-label" uses caused doctors to prescribe Trisenox to treat various forms of cancer for which the drug was neither approved by the FDA,

Cephalon General Counsel John Osborn Nominated by President Bush ...  -  May 16, 2007
PR Newswire (press release),TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride),

Cell Therapeutics, Inc. (CTI) Announces First Quarter 2007 ...  -  May 2, 2007
PharmaLive.com (press release),...of allegations regarding alleged overpayments by Medicare to doctors who prescribed the anti-cancer drug, TRISENOX, with a full release from liability

Cephalon Expects First Quarter 2007 Results to Exceed Expectations  -  26 Apr 2007
MSN MoneyGABITRIL(R) (tiagabine hydrochloride), TRISENOX(R) (arsenic trioxide) injection, and VIVITROL(R) (naltrexone for extended-release injectable suspension)

Cell Therapeutics, Inc. to Pay United States $10.5 Million to ...  -  Apr 18, 2007
PressZoom (press release),The alleged “off-label� uses caused doctors to prescribe Trisenox to treat various forms of cancer for which the drug was neither approved by the FDA nor

Cell Therapeutics to Pay $10.5 Million Settle False Claims Act Case  -  Apr 18, 2007
Corporate Crime Reporter,Federal officials alleged that the company illegally marketed the anti-cancer prescription drug Trisenox drug for various uses that were not approved by the

Cell Therapeutics settles complaint alleging improper marketing ...  -  Apr 17, 2007
Seattle Times,Cell Therapeutics used illegal kickbacks to entice physicians to prescribe its cancer drug Trisenox, sometimes paying physicians up to $1000 to attend

Cell Therapeutics, Inc. to Pay United States $10.5 Million to ...  -  Apr 17, 2007
PR-Inside.com (Pressemitteilung),The government's suit alleged that because of the company's actions, physicians who prescribed Trisenox "off-label" unwittingly submitted false claims for

Cell Therapeutics to pay $10.5 million to settle feds' suit  -  Apr 18, 2007
Seattle Times,Cell Therapeutics also paid doctors who were high-volume prescribers of Trisenox up to $1500 in "illegal kickbacks," for speaking at meetings promoting the

Cell Therapeutics Settles Complaint  -  Apr 17, 2007
Forbes,The Department of Justice said Tuesday Cell Therapeutics Inc. agreed to pay $10.5 million to resolve allegations that it illegally marketed Trisenox,

Cell Therapeutics Settles Complaint  -  Apr 17, 2007
Houston Chronicle,Additionally, Cell Therapeutics allegedly gave doctors kickbacks to induce them to prescribe Trisenox, including being paid between $500 and $1000 to attend

Cell Therapeutics settles lawsuit for $10.5 million  -  Apr 18, 2007
Pharmaceutical Business ReviewThe company had already taken a charge in the fourth quarter of 2006 for an agreement with the government about the investigation into Trisenox promotional

Cell Therapeutics settles law suit with Government  -  Apr 18, 2007
News-Medical.net,CTI transferred all rights, title and interest in TRISENOX(R) to Cephalon in July 2005. James A. Bianco, MD, President and CEO, stated, "We were proud to

Cell Therapeutics settles with US for $10.5M  -  Apr 17, 2007
Bizjournals.com,Cell Therapeutics (NASDAQ: CTICD) in 2005 sold its rights and interest in Trisenox to Pennsylvania-based Cephalon Inc. The agreement resolves a federal

Cell Therapeutics agrees to $10.5 million settlement  -  Apr 17, 2007
Seattle Post Intelligencer,The government alleged in a complaint that Cell Therapeutics promoted various uses of the anti-cancer drug Trisenox even though it had received FDA approval

CTI settles government suit for $10.5M  -  Apr 17, 2007
BusinessWeekThe government's suit against Cell Therapeutics claimed the company marketed its Trisenox leukemia drug to doctors as an effective treatment against other

UPDATE 1-Cell Therapeutics settles claims over cancer drug  -  Apr 17, 2007
ReutersO: Quote, Profile, Research) has agreed to pay $10.5 million to resolve allegations of illegal marketing of its anti-cancer prescription drug Trisenox,

Cell Therapeutics to pay $10.5 mln to settle charges - DoJ  -  Apr 17, 2007
ReutersO: Quote, Profile, Research) has agreed to pay $10.5 million to resolve allegations of illegal marketing of the anti-cancer prescription drug Trisenox,

Cell Therapeutics settles off-label marketing suit for $10.5 million  -  Apr 17, 2007
KNDO/KNDU,The government says Cell Therapeutics marketed its Trisenox leukemia drug as a treatment for other cancers. The Justice Department says doctors who received

Cell Therapeutics (CTIC) Settles Qui Tam Suit with Government  -  Apr 17, 2007
StreetInsider.com (subscription),...of Justice investigation into allegations regarding alleged overpayments by Medicare to doctors who prescribed the anti-cancer drug, TRISENOX.

Cephalon Provides Update Related to NUVIGIL(TM) New Drug Application  -  Apr 3, 2007
Drug Newswire (press release),GABITRIL(R) (tiagabine hydrochloride), TRISENOX(R) (arsenic trioxide) injection, and VIVITROL(R) (naltrexone for extended-release injectable suspension)

Cephalon Files Marketing Application for Approval of a Fentanyl ...  -  Mar 29, 2007
Drug Newswire (press release),The company's products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA, TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R)

Cephalon Files Marketing Application For Approval Of A Fentanyl ...  -  27 Mar 2007
Medical News Today (press release),The company's products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA, TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R)

Cell Therapeutics, Inc. (CTI) Reports 2006 Fourth Quarter and Year ...  -  Mar 15, 2007
MSN MoneyThis compares to a net loss of $102.5 million ($1.59 per share), which included a $71.2 million gain for the year on the divestiture of TRISENOX as well as

Cell Therapeutics Q4 Loss Widens; Revenue Declines - Quick Facts  -  Mar 15, 2007
Trading Markets,The year-ago quarter loss included a $40.7 million gain on the divestiture of TRISENOX and a $23.6 million charge for the conversion of $38.4 million of the

Cephalon Reports Record Sales and Earnings for 2006  -  Feb 12, 2007
PR Newswire (press release),...net of cash acquired - (130733) Acquisition of TRISENOX - (69722) Acquisition of Zeneus, net of cash acquired - (365786) Acquisition of intangible

Cephalon Reports Record Sales and Earnings for 2006  -  Feb 15, 2007
Drug Newswire (press release),FENTORA(TM) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide), VIVITROL(R) (naltrexone for extended-release injectable suspension),

Cephalon, Inc. Promotes Mike Barr to Vice President  -  Feb 12, 2007
Drug Newswire (press release),FENTORA, ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II], GABITRIL(R) (tiagabine hydrochloride), TRISENOX(R) (arsenic trioxide) injection,

Cephalon, Inc. Promotes Mike Barr to Vice President  -  Feb 7, 2007
Yahoo! News (press release)GABITRIL® (tiagabine hydrochloride), TRISENOX® (arsenic trioxide) injection, and VIVITROL® (naltrexone for extended-release injectable suspension).

Going Global  -  Jan 26, 2007
Red Herring,On January 24, its arsenic compound, Trisenox, was shown to improve survival rates of adults with acute proyelocytic leukemia (AML), a rare form of leukemia

Cephalon Announces Positive Results from Two Phase 3 Clinical ...  -  Jan 9, 2007
Yahoo! News (press release)The company currently markets six proprietary products in the United States: PROVIGIL® (modafinil) Tablets [C-IV], FENTORA, TRISENOX® (arsenic trioxide)

Cephalon Announces Positive Results from Two Phase 3 Clinical ...  -  Jan 9, 2007
PR Newswire (press release),The company currently markets six proprietary products in the United States: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA, TRISENOX(R) (arsenic trioxide)

Cephalon Reduces Outstanding Convertible Debt by $337 Million  -  Dec 19, 2006
Drug Newswire (press release),GABITRIL(R) (tiagabine hydrochloride), TRISENOX(R) (arsenic trioxide) injection, and VIVITROL(R) (naltrexone for extended-release injectable suspension)

Cephalon Reduces Outstanding Convertible Debt by $337 Million  -  26 Dec 2006
Drug Newswire (press release),GABITRIL(R) (tiagabine hydrochloride), TRISENOX(R) (arsenic trioxide) injection, and VIVITROL(R) (naltrexone for extended-release injectable suspension)

Cephalon Reduces Outstanding Convertible Debt by $337 Million  -  Dec 19, 2006
Yahoo! News (press release)GABITRIL® (tiagabine hydrochloride), TRISENOX® (arsenic trioxide) injection, and VIVITROL® (naltrexone for extended-release injectable suspension).

Cell Therapeutics' loss falls below estimates  Nov 7, 2006
The 2005 figure included a $30.5 million gain from the divestiture of Trisenox. Analysts had estimated a loss between 20 and 26 cents. ... -Seattle Post Intelligencer TABLE-Cell Therapeutics Q3 loss widens  Nov 7, 2006
...--The biopharmaceutical company said latest third-quarter results included a gain of $30.5 million related to its divestiture of Trisenox in July 2005. ... -Reuters Cell Therapeutics, Inc. (CTI) Reports Third Quarter 2006 Financial ...  Nov 7, 2006
The net loss for both the quarter and nine months ended September 30, 2005, included a $30.5 million gain related to our divestiture of TRISENOX in July 2005. ... -Yahoo! News (press release) Cephalon Inc. Granted Composition of Matter Patent Covering ...  Nov 7, 2006
FENTORA(TM) (fentanyl buccal tablet) [C-II], ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II], GABITRIL(R) (tiagabine hydrochloride), TRISENOX(R) (arsenic ... -Drug Newswire (press release), Cephalon Third-Quarter Earnings More Than Double  Nov 2, 2006
Purchases of property and equipment (97,122) (63,951) Acquisition of Salmedix, net of cash acquired - (130,733) Acquisition of TRISENOX - (69,722) Acquisition ... -Earthtimes.org Cephalon Announces Positive Results For FENTORA(TM) (fentanyl ...  Oct 12, 2006
The company currently markets six proprietary products in the United States: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA, TRISENOX(R) (arsenic trioxide ... -Medical News Today (press release), Cephalon Announces Positive Results for FENTORA(TM) (fentanyl ...  Oct 11, 2006
The company currently markets six proprietary products in the United States: PROVIGIL® (modafinil) Tablets [C-IV], FENTORA, TRISENOX® (arsenic trioxide ... -Yahoo! News (press release) Friday Roundup: Shame on Who?, Merck AG, Tis' The Season  Sep 22, 2006
On Thursday, we find out the US Attorney’s office is sending in subpoenas relating to CTI’s marketing of Trisenox – specifically, the alleged practice of ... -Minyanville.com

CTI, Novartis Enter Xyotax Deal; Option On Pixantrone  Sep 18, 2006
That would allow CTI to rebuild a sales force; the company shed that department last year after selling the leukemia drug Trisenox (arsenic trioxide) to Frazer ... -BioWorld Online

World News | Novartis boosts cancer pipeline with $285m deal - 19 ...  Sep 19, 2006
This was disbanded after the company sold rights to its Trisenox (arsenic trioxide) leukaemia drug to Cephalon for $170 million last year, in order to fund ... -Pharma Times (subscription)

Dismissal ends suits over Xyotax  Sep 13, 2006
The US Attorney's Office is also investigating whether Cell Therapeutics unlawfully promoted Trisenox, a leukemia drug it owned from 2000 to 2005, for other ... -Seattle Times

ZIOPHARM Presents at European Society of Hematology Meeting ...  Sep 14, 2006
ZIO-101 can be safely given at significantly higher doses than inorganic arsenics, like arsenic trioxide (Trisenox(R)). Based on these encouraging data ... -International News Service

Cephalon, Inc. Appoints Dr. Lesley Russell as Senior Vice ...  Aug 25, 2006
PROVIGIL® (modafinil) Tablets [C-IV], GABITRIL® (tiagabine hydrochloride), ACTIQ® (oral transmucosal fentanyl citrate) [C-II], TRISENOX® (arsenic trioxide ... -Yahoo! News

Cephalon, Inc. Appoints Dr. Lesley Russell as Senior Vice ...  Aug 25, 2006
PROVIGIL(R) (modafinil) Tablets [C-IV], GABITRIL(R) (tiagabine hydrochloride), ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II], TRISENOX(R) (arsenic ... -Drug Newswire

Cephalon Provides Update Related To Final NUVIGIL(TM) Labeling  -  Dec 8, 2006
Medical News Today (press release),GABITRIL(R) (tiagabine hydrochloride), TRISENOX(R) (arsenic trioxide) injection, and VIVITROL(R) (naltrexone for extended-release injectable suspension)

Cephalon Provides Update Related to Final NUVIGIL(TM) Labeling  -  Dec 7, 2006
Yahoo! News (press release)GABITRIL® (tiagabine hydrochloride), TRISENOX® (arsenic trioxide) injection, and VIVITROL® (naltrexone for extended-release injectable suspension).

Pharmion and Nippon Shinyaku Announce Licensing Agreement for ...  -  Nov 22, 2006
PipelineReview.com (press release),Nippon Shinyaku currently markets Cylocide(R) and Cylocide(R) N for acute leukemia and malignant lymphoma, and Trisenox(R) and Amnolake(R) both for relapsed

Pharmion and Nippon Shinyaku Announce Licensing Agreement for ...  -  Nov 20, 2006
Yahoo! News (press release)Nippon Shinyaku currently markets Cylocide® and Cylocide® N for acute leukemia and malignant lymphoma, and Trisenox® and Amnolake® both for relapsed or

Cephalon, Inc. Appoints Dr. Lesley Russell as Senior Vice ...  Aug 25, 2006
PROVIGIL® (modafinil) Tablets [C-IV], GABITRIL® (tiagabine hydrochloride), ACTIQ® (oral transmucosal fentanyl citrate) [C-II], TRISENOX® (arsenic trioxide ... -Yahoo! News

Cell Therapeutics Trims 2Q Loss  Aug 8, 2006
Revenue fell to $20,000 from $7.5 million last year, following the sale of rights to leukemia treatment Trisenox to Cephalon in July. ... -Houston Chronicle

Cephalon, Inc. Appoints Dr. Lesley Russell as Senior Vice ...  Aug 25, 2006
PROVIGIL(R) (modafinil) Tablets [C-IV], GABITRIL(R) (tiagabine hydrochloride), ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II], TRISENOX(R) (arsenic ... -Drug Newswire

Cephalon Second-Quarter Sales Increase 58 Percent  Aug 3, 2006
The company currently markets five proprietary products in the United States: PROVIGIL, GABITRIL(R) (tiagabine hydrochloride), ACTIQ, TRISENOX(R) (arsenic ... -MSN Money

Cephalon Second-Quarter Sales Increase 58 Percent  Aug 3, 2006
...company currently markets five proprietary products in the United States: PROVIGIL, GABITRIL® (tiagabine hydrochloride), ACTIQ, TRISENOX® (arsenic trioxide ... -Yahoo! News

Cell Therapeutics: Cytotoxic to Shareholders?  Jul 27, 2006
Balance Sheet Weaknesses Limit Financial Flexibility: TRISENOX was, prior to its divestiture to Cephalon in July 2005, the Company’s only commercial product ... -Seeking Alpha

Cephalon Receives Approvable Letter for FENTORA(TM) (fentanyl ...  Jun 29, 2006
PROVIGIL® (modafinil) Tablets [C-IV], GABITRIL® (tiagabine hydrochloride), ACTIQ® (oral transmucosal fentanyl citrate) [C-II], TRISENOX® (arsenic trioxide ... -Yahoo! News

Cephalon Receives Approvable Letter For FENTORA(TM) (fentanyl ...  Jun 30, 2006
PROVIGIL(R) (modafinil) Tablets [C-IV], GABITRIL(R) (tiagabine hydrochloride), ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II], TRISENOX(R) (arsenic ... -Medical News Today

Cephalon Announces Results from GABITRIL(R) Clinical Program in ...  Jun 26, 2006
...in the United States: PROVIGIL® (modafinil) Tablets [C-IV], GABITRIL, ACTIQ® (oral transmucosal fentanyl citrate) [C-II], TRISENOX® (arsenic trioxide ... -Yahoo! News

Cephalon Announces Results from GABITRIL(R) Clinical Program in ...  Jun 26, 2006
...products in the United States: PROVIGIL(R) (modafinil) Tablets [C-IV], GABITRIL, ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II], TRISENOX(R) (arsenic ... -Drug Newswire



Cell Therapeutics, Inc. (CTI) Announces First Quarter 2006 ...  May 4, 2006
There were no net product sales for TRISENOX(R) (arsenic trioxide) for the quarter ended March 31, 2006, as a result of its divestiture to Cephalon in July 2005 ... - PharmaLive.com

Earnings: Puget Energy revenue up 18% after sale of subsidiary  May 4, 2006
It said the drop resulted from the absence of product sales for the company's Trisenox leukemia drug, as a result of its divestiture to Caphalon in July 2005. ... - Seattle Post Intelligencer

Cephalon's Fentanyl Effervescent Buccal Tablet Reduces Intensity ...  May 5, 2006
PROVIGIL(R) (modafinil) tablets [C-IV], GABITRIL(R) (tiagabine hydrochloride), ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II], and TRISENOX(R) (arsenic ... - Medical News Today

Cephalon Reports First-Quarter Financial Results  May 2, 2006
PROVIGIL (modafinil) Tablets [C-IV], GABITRIL® (tiagabine hydrochloride), ACTIQ® (oral transmucosal fentanyl citrate) [C-II], and TRISENOX® (arsenic trioxide ... - Yahoo! News

Cephalon Receives Approvable Letter for NUVIGIL(TM) (armodafinil)  May 1, 2006
...in the United States: PROVIGIL, GABITRIL® (tiagabine hydrochloride), ACTIQ® (oral transmucosal fentanyl citrate) [C-II], and TRISENOX® (arsenic trioxide ... - Yahoo! News

Cephalon Receives Approvable Letter for NUVIGIL (armodafinil)  May 1, 2006
...products in the United States: PROVIGIL, GABITRIL(R) (tiagabine hydrochloride), ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II], and TRISENOX(R) (arsenic ... - PharmaLive.com

Cephalon Reports First-Quarter Financial Results  May 2, 2006
PROVIGIL (modafinil) Tablets [C-IV], GABITRIL(R) (tiagabine hydrochloride), ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II], and TRISENOX(R) (arsenic ... - PharmaLive.com

Antisoma appoints Dr Gary Acton as Chief Medical Officer  Apr 23, 2006
...he was European Managing Director of Cell Therapeutics, Inc, where he led the successful application for European marketing approval of the cancer drug Trisenox ... - Market Wire

Cephalon, Inc. Provides Update on Regulatory Status of SPARLON(TM)  Apr 24, 2006
...modafinil) Tablets [C-IV], GABITRIL® (tiagabine hydrochloride), ACTIQ® (oral transmucosal fentanyl citrate) [C-II] and TRISENOX® (arsenic trioxide) injection ... - Yahoo! News

Cephalon, Inc. Provides Update on Regulatory Status of SPARLON(TM)  Apr 24, 2006
PROVIGIL(R) (modafinil) Tablets [C-IV], GABITRIL(R) (tiagabine hydrochloride), ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II] and TRISENOX(R) (arsenic ... - PR Newswire





Cell Therapeutics Reports Narrower Q4 Loss; Revenues Decline On ...  Mar 9, 2006
The quarterly results included $40.7 million gain on TRISENOX divestiture and a $23.6 million charge for the conversion senior subordinated notes. ... - Trading Markets

Seattle biotech firm's drug marketing in question  Mar 16, 2006
...that prosecutors with the US Attorney's Office for Western Washington were looking at the company's handling of its only federally approved drug, Trisenox. ... - Seattle Post Intelligencer

Cephalon Oncology Compound Lestaurtinib (CEP-701) Granted Orphan ...  Apr 4, 2006
The Cephalon Oncology portfolio includes three lead compounds targeted for patients with hematologic cancers: TRISENOX® (arsenic trioxide) injection, an ... - Yahoo! News

Cephalon Oncology Compound Lestaurtinib (CEP-701) Granted Orphan ...  Apr 4, 2006
Cephalon Oncology Portfolio The Cephalon Oncology portfolio includes three lead compounds targeted for patients with hematologic cancers: TRISENOX(R) (arsenic ... - PR Newswire

Cell Therapeutics discloses probe info  Mar 17, 2006
Cell Therapeutics first said last summer the US Attorney's Office was investigating its business practices related to Trisenox, a drug approved by the Food and ... - Seattle Times

Cell Therapeutics, Inc. (CTI) Reports 2005 Fourth Quarter and Year ...  Mar 9, 2006
This included a $40.7 million gain in the quarter on the divestiture of TRISENOX(R) and a $23.6 million charge for the conversion of $38.4 million related to ... - MSN Money

Cell Therapeutics 4Q Loss Narrows  Mar 9, 2006
...company focused on cancer drugs, on Thursday posted a smaller loss for the fourth quarter on a hefty gain from the sale of its leukemia treatment Trisenox. ... - MSN Money

Cephalon Granted Six Months of Pediatric Exclusivity for PROVIGIL  Mar 28, 2006
...in the United States: PROVIGIL, GABITRIL(R) (tiagabine hydrochloride) Tablets, ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II], and TRISENOX(R) (arsenic ... - PharmaLive.com

TABLE-Cell Therapeutics Q4 loss narrows  Mar 9, 2006
...--The biopharmaceutical company said the latest quarter included a gain of $40.7 million on the divestiture of Trisenox and a charge of $23.6 million for the ... - Reuters

FDA Advisory Committee Recommends Against Approval of SPARLON(TM) ...  Mar 23, 2006
...the United States: PROVIGIL, GABITRIL® (tiagabine hydrochloride) Tablets, ACTIQ® (oral transmucosal fentanyl citrate) [C-II], and TRISENOX® (arsenic trioxide ... - Yahoo! News

Earnings: Profit caps busy quarter for Cutter & Buck  Mar 9, 2006
Cell Therapeutics recorded a $71.2 million gain for the year on its divestiture of the drug Trisenox. It is now focusing on Xyotax, an anti-cancer drug. ... - Seattle Post Intelligencer



Cell Therapeutics: hoping for a rich performance  Feb 9, 2006
Indeed, having dispensed of Trisenox to help fund further development of Xyotax, Cell Therapeutics will be putting all of its might behind the drug and, with ... - Pharmaceutical Business Review

Cephalon, Inc. Provides Update on Regulatory Status of NUVIGIL(TM)  Feb 1, 2006
...products in the United States: PROVIGIL, GABITRIL(R) (tiagabine hydrochloride), ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II] and TRISENOX(R) (arsenic ... - PR Newswire,

Cephalon, Inc. Announces Agreements With Barr Laboratories, Inc. ...  Feb 1, 2006
...company currently markets four proprietary products in the United States: PROVIGIL, GABITRIL® (tiagabine hydrochloride), ACTIQ and TRISENOX® (arsenic trioxide ... - Yahoo! News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional